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Infectious disease in the developing world continues to 
represent one of the greatest challenges facing humanity. 
Every year over a million children suffer and die from the 
sequela of enteric infections, and in 2008 was estimated 
almost 2.7 million (UNAIDS 2009 update) adults and children 
became infected with human immunodeficiency virus (HIV). 
While oral rehydration therapy for diarrhea and antiretrovirals 
(ARV) for HIV are critical, there is a place for adjunctive 
therapies to improve quality of life. The importance of the 
human microbiota in retaining health is now recognized, as 
is the concept of replenishing beneficial microbes through 
probiotic treatments. Studies have shown that probiotics can 
reduce the duration of diarrhea, improve gut barrier function, 
help prevent bacterial vaginosis (BV) and enhance immunity 
even in HIV-infected subjects. However, many issues remain 
before the extent of probiotic benefits can be verified, and 
their application to the developing world realized. This 
consensus report outlines the potential probiotic, and to a 
lesser extent prebiotic, applications in resource disadvantaged 
settings, and recommends steps that could bring tangible 
relief to millions of people. The challenges to both efficacy 
and effectiveness studies in these settings include a lack of 
infrastructure and funding for scientists, students and research 
projects in developing countries; making available clinically 
proven probiotic and prebiotic products at affordable prices; 
and undertaking appropriately designed clinical trials. We 
present a roadmap on how efficacy studies may be conducted 
in a resource disadvantaged setting among persons with 
chronic diarrhea and HIV. These examples and the translation 
of efficacy into effectiveness are described.
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MEETING REPORT
Introduction
Many citizens of developing countries face extreme challenges 
every day of their life. The term ‘resource disadvantaged’ is gen-
erally accepted to describe areas with a low gross domestic prod-
uct and with a below-average human quality of life index. Many 
countries in Africa, Southeast Asia and the Middle East fit this 
profile.1
In addition to personal safety concerns, access to high qual-
ity food and clean water is a daily struggle.2 This, and a lack 
of adequate daily nutrient intake, is particularly devastat-
ing for children. A 2008 World Health Organization (WHO) 
regional review showed that infectious diseases are responsible 
for the majority of deaths among children <5 years of age.3 An 
estimated four billion cases of diarrhea are reported yearly lead-
ing to over two million deaths, mostly among children residing 
in areas without access to clean water, latrines, healthcare and 
adequate nutrition. Diarrhea is caused by a wide range of micro-
bial pathogens leading to the passage of loose or liquid stools 
more frequently than normal.4 Of these, rotavirus infections in 
children are one of the most common, although they generally 
pass without complications as long as oral rehydration therapy is 
administered. The introduction of a vaccine against rotaviruses 
along with oral rehydration salts, zinc, antibiotics for dysentery, 
vitamin A supplementation, sanitation, hygiene and breastfeed-
ing has been stated to avert five million deaths.5
However, enterotoxigenic bacteria such as Escherichia coli, 
Shigella, Campylobacter and Salmonella, as well as Vibrio cholera 
can produce a number of virulence factors that induce a fatal 
outcome.6,7
Confounding the burden of disease on these resource disad-
vantaged areas is the global epidemic of HIV, the prevalence of 
which has increased in women through heterosexual contact. In 
some countries, the prevalence is as high as 35% amongst the 
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cytokine production, the type upregulated depends on the strain 
but include; inflammatory [tumor necrosis factor alpha (TNFα), 
gamma interferon (IFNγ); and interleukin-12 (IL-12)] and regu-
latory (IL-4, IL-10) cytokines.15,16 Gill et al. reported an increase 
in IFNγ and IL-4 production from 100 units/ml to 200 units/
ml or higher following addition of strains of Lactobacillus rham-
nosus, L. acidophilus and Bifidobacterium lactis versus controls in 
mice. Thirdly, beneficial microbes, from which probiotic strains 
are selected, often express factors such as bacteriocins, hydrogen 
peroxide and other antimicrobials that kill pathogens or inhibit 
their growth.18-20 They may also release signaling molecules that 
downregulate toxin production or release by pathogens,21-23 as 
well as interfere with binding of pathogens to receptor sites on 
the gut mucosa.24
Probiotics for Diarrhea
There have been many studies on the use of probiotics to help 
treat diarrhea, but it has generally been accepted that the main 
role is to prevent this condition.11 A meta-analysis has shown that 
at least two strains, L. rhamnosus GG and Saccharomyces cerevi-
siae subsp. boulardii Lyo, are effective in reducing the duration 
of diarrhea when supported by oral rehydration.25 In addition, 
there is some evidence that probiotics can reduce episodes of diar-
rhea, severity of symptoms, vomiting and fever.26 Two Cochrane 
reports have recently been published on the topic. In one, the 
aim was to assess the effects of probiotics in proven or presumed 
acute infectious diarrhea.27 Although the report claimed that 
63 studies met the inclusion criteria with a total of 8,014 par-
ticipants, their inclusion criteria of what constitutes a probiotic 
(by definition11) was flawed and even reported a study with dead 
lactobacilli. Nevertheless, the analysis concluded that probiotics 
provide tangible benefits in shortening the duration and reducing 
stool frequency in acute infectious diarrhea, when used with oral 
dehydration. Given that some probiotic interventions come in 
liquid form, it would be interesting to perform a meta-analysis of 
the efficacy of these products in cases where oral rehydration was 
not available or used. In the second recent meta-analysis, four 
trials with 464 participants were assessed to evaluate probiotics 
for treating persistent diarrhea (lasting more than 14 days) in 
children.28 The authors concluded that evidence for probiotics to 
ameliorate this condition was limited. Clearly, the root cause of 
the diarrheal persistence needs to be addressed before expecting 
probiotics or any other intervention to be successful. In a study 
of 571 children aged 3–36 months visiting a family paediatrician 
for acute diarrhea, the type of probiotic agent used had profound 
effects, with L. rhamnosus GG being the most effective in reduc-
ing duration of diarrhea.29
The administration of probiotics to children facing chronic 
diarrhea is of great importance for more than just gut health. 
While diarrhea may be life threatening if severe and untreated, 
infants who suffer from frequent episodes or chronic diarrhea 
tend to have stunted growth (low height for-age, a marker of 
chronic malnutrition), abnormally low body mass indices and 
impairment of cognitive function with detrimental lifelong 
consequences.30-32
adult population aged 15–49.8 This devastates the work force, 
including teachers and caregivers, and leads to orphans and a 
breakdown of family structures. Diarrhea is highly prevalent in 
HIV-infected subjects and compounds the inability to absorb 
nutrients, decreases energy to carry out daily activities and 
reduces the ability to tolerate anti-retroviral treatment (ART).9,10
While great strides have been made to provide water purifica-
tion systems and inexpensive or free pharmaceutical agents to 
treat infections and stabilize immunity, millions of people par-
ticularly in rural areas and high density urban slums still suffer 
from conditions, which in the developed world are manageable. 
Of the armamentarium of agents used to manage diarrhea, pro-
biotics defined as ‘live microorganisms which when administered 
in adequate amounts confer a health benefit on the host’11 are 
increasingly explored.
Workshop Objectives
In August 2010, a workshop was hosted by the International 
Scientific Association for Probiotics and Prebiotics (ISAPP) to 
discuss the rationale for global application of probiotics. Two 
conditions identified as potentially receptive to probiotic inter-
vention include diarrheal diseases and complications associated 
with HIV infection. A previous closed workshop on a similar 
topic was held in the UK in 2010 by the Bill and Melinda Gates 
Foundation, but the present meeting is the first to openly dis-
cuss findings from a review of the literature by researchers with 
experience working in resource disadvantaged regions and with 
knowledge of probiotics. Although no representative from an 
African nation was able to attend, several scientists with experi-
ence with this region did participate, thus each continent had 
representation.
Three objectives were established:
(1) Apply the scientific rationale for using probiotics and/or 
prebiotics to combat diarrheal diseases and assist with the adverse 
events and treatment regimens associated with HIV to improve 
outcomes.
(2) Design evaluations to determine the optimal probiotic and 
prebiotic for specific conditions and populations.
(3) Discuss the development of strategies for local production, 
distribution, and uptake of probiotics and prebiotics.
Scientific Rationale for Probiotic Use
The rationale for use of probiotics in children and adults in 
resource disadvantaged regions comes from essentially three fac-
tors. First, the role the microbiota plays in the maintenance of 
the epithelial barrier function of the gut. Studies have shown that 
bacteria can upregulate tight junction proteins and increase resis-
tance of the cell layer.12,13 An intact epithelium is required for 
efficient nutrient uptake in a healthy host.14 Secondly, microbes 
play a role in modulating innate and acquired immunity in a 
manner that protects the host from infection. Certain strains of 
Lactobacillus casei have been shown to stimulate immunoglobulin 
IgA production, increasing basal levels of this circulating anti-
body. In addition numerous strains have been shown to increase 
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Diarrheal Disease-Proposed Study Design  
for Future Study
If probiotic-based therapies are to be incorporated into global 
health strategies to reduce the burden of enteric and diarrheal 
diseases, target populations must be carefully identified45 with a 
high likelihood of responders.46 Such studies follow a random-
ized, double masked, placebo-controlled protocol with primary 
endpoints of: reduction of diarrhea episodes, decline in hospital 
visits, mortality and a general improvement in public health, with 
follow-up for at least one year. In addition, secondary endpoints 
should include the impact on stunting, weight and cognitive 
defects. As high population density urban slums are often sites 
of frequent/severe diarrhea outbreaks in resource disadvantaged 
countries, these would provide ideal populations to study the 
direct effects of probiotics or prebiotics/synbiotics on treating 
diarrhea and improving symptoms. A clinical trial conducted 
in Kolkata, India showed that probiotic Lactobacillus casei strain 
Shirota could reduce episodes of acute diarrhea during a 24 week 
follow.47 However, that study did not take into account weight, 
height and other biomarkers which can be valuable sources of 
data explaining what is occurring in the gut microbiota as a result 
of intervention. It may be possible broadening the outcomes to 
analyze and applying different organisms in a different dose may 
change the study outcome.
An additional point of extreme importance is that the study 
materials (yogurt, sachet) should be either in a form that is afford-
able to the population being tested, or after the trial it will be 
made available for an extended period of time to the community. 
One method to establish this is to create a local economy for pro-
duction and distribution of the product as has been achieved in 
several African countries using probiotic yogurt.38,48 This is criti-
cal, otherwise the local community see the benefits of an effective 
intervention which they played a part in, only for the product to 
disappear from their neighborhood. This is exploitative, demor-
alizing and creates an outcomes gap.
In order to turn the introduction of probiotics in resource poor 
countries into a sustainable and large-scale operation, it is essen-
tial to provide long-term access to probiotic products by creating 
a local infrastructure for their production and distribution. This 
provision of affordable products can be based upon commercial 
Bottom of Pyramid (BoP) principles.49 Accordingly, increase of 
health and wealth can be achieved by creating the appropriate 
distribution channels, assuring affordability of the product, and/
or increasing buying power and dedicated consumer education. 
Initiatives aimed at the distribution of license-free probiotic 
starter cultures could enable local communities with existing 
yogurt production facilities to upgrade their product portfolio 
with probiotics at a minimal cost increase, such as with a Dutch 
initiative in Uganda.50 This approach not only introduces afford-
able health products in the region, it also increases income for 
farmers, producers and local distributors. One of the low-cost but 
effective ways to inform people about the potential benefits of the 
probiotic products include local radio stations or the M-Health 
concept which could potentially reach people via mobile elec-
tronic devices.51 Complementary partnerships with health care 
Probiotics for HIV
Probiotics appear to support maintenance of a strong gut epi-
thelia layer33 and stimulation of innate immunity34 which act as 
the first layer of defense against translocation of viral particles 
and bacterial pathogens.35 There is preliminary evidence that L. 
rhamnosus GR-1 in yogurt and a combination of Bifidobacterium 
bifidum with Streptococcus thermophilus can confer some immu-
nostimulatory activity in adults and children.36-38 In addition, the 
nutrients in yogurt and the ability of probiotics to improve gut 
barrier function likely also play a role in enhancing nutritional 
and immune competence.39
The Role for Prebiotics in Amelioration of Diarrhea
Defined as ‘the selective stimulation of growth and/or 
activity(ies) of one or a limited number of microbial genus(era)/
species in the gut microbiota that confer(s) health benefits to 
the host’,40 prebiotics have been used in resource disadvantaged 
settings for diarrhea treatment. Intriguingly, a recent study 
showed that a hypotonic oral rehydration solution (ORS) con-
taining zinc and prebiotics (0.35 g/L xylooligosaccharides) was 
more effective at resolving diarrhea at 72 hours than regular 
oral rehydration therapy in young children.41 Such prebiotic 
products could potentially be made available in countries where 
no cold chain storage and transportation exists to maintain the 
viability of probiotic foods and supplements. Another prebiotic, 
galacto-oligosaccharide mixture (5.5 g) was shown to be better 
than maltodextran at reducing the severity and/or incidence of 
travellers’ diarrhea (TD) in healthy subjects who stayed in a 
country of low or high risk for TD for a minimum of 14 days 
and a maximum of 60 days.42 High-risk destinations included 
Asia, The Middle East, Africa, Mexico, Central and South 
America, while low-risk areas included Turkey, South Africa 
and The Caribbean Islands.
The combining of probiotics with prebiotics into a ‘synbi-
otic’ product has been promoted as enhancing the effects of 
single agents. However, results have been mixed. In a random-
ized, double-masked, controlled trial, healthy newborns >35 
weeks of gestational age and >1,800 g birth weight were ran-
domized between 1 and 3 days after birth to receive an oral 
synbiotic preparation (Lactobacillus plantarum and fructooligo-
saccharides) or a dextrose saline placebo for 7 days.43 The main 
outcomes were persistence of the lactobacilli and reduction in 
Gram-negative species in the infant gut. The application of a 
synbiotic (Synbiotic 2000 Forte) freeze-dried food (containing 
Pediococcus pentosaceus 16:1 LMG P-20608, Leuconostoc mes-
enteroides 23–77:1 LMG P-20607, Lactobacillus paracasei ssp 
paracasei F-19 LMG P-17806 and Lactobacillus plantarum 2362 
LMG P-20606 and oat bran [rich in β-glucans], inulin, pectin 
and resistant starch) to 399 Malawian infants did not result 
in detectable improvements in nutritional status or secondary 
outcomes such as diarrhea reduction.44 Prebiotic and synbiotic 
products need to be further studied if their primary goal is to 
impact the gut health of children in resource disadvantaged 
areas.
©2011 Landes Bioscience.
Do not distribute.
www.landesbioscience.com Gut Microbes 201
Several other biomarkers should be studied, such as serum 
lipopolysaccharide (LPS) or anti-LPS core antibody levels to 
measure inflammation, lactulose and mannitol to asses gut bar-
rier and nutrient absorption,59,60 nutritional assessments to get 
a clear understanding of each child’s specific situation, height, 
weight, head circumference and IQ scores.61 Long-term reduc-
tions in cognitive function as assessed by the relative language- 
and culture-independent TONI-III test have correlated with 
more frequent episodes of diarrhea.57 Taking baseline measure-
ments of cognitive function and comparing after study comple-
tion may reveal the immediate impact, if any, that probiotics and 
nutrition can have on improving this factor. However, long-term 
assessments that include cognitive testing (such as TONI-III or 
Raven scores) at >4–6 years of age may be necessary.
It is well known that children suffering from chronic or recur-
rent diarrhea are often stunted and thinner. Increases in weight 
with probiotic treatment can be viewed as a positive change imply-
ing improvements in gut health and nutrient uptake. A microbi-
ota study of fecal samples will help determine what organisms are 
dominant in healthy vs. diarrhea subjects. Such studies have been 
performed in favellas in Brazil using culture-based techniques,62 
so it is feasible. However, without on-site facilities and expertise 
with culturing methods, at the very least samples should be col-
lected at time of study for later processing by sequencing methods 
such as Illumina63,64 to profile the depth of microbes present and 
their relative abundance.
HIV-Study Design
The global threat of HIV/AIDS has been well documented in 
recent history. Although prevalence of the virus is still exceed-
ingly high, in many African countries reported rates are decreas-
ing. This positive trend is likely due to the increased investment 
of resources in these countries and improving education on the 
disease and its prevention. Many of the current treatments for 
HIV focus on antiviral drugs, and the discovery of effective vac-
cines. While these endeavours are noble, they do not answer the 
question of how can we make an immediate improvement in the 
quality of life and outcomes for people already infected by HIV.
As stated above, the gut barrier is a natural defense mecha-
nism preventing translocation of pathogens into the blood-
stream. This barrier becomes damaged in HIV infected subjects, 
leading to inflammation and the increased ability of pathogens 
to cause bacteremia via translocation.65 Studies suggest that pro-
biotics can aid in repair of the damaged epithelial barrier and 
help prevent pathogen translocation.66 HIV infects and destroys 
T cells, including Th 17 CD4+ T cells that mediate host defenses 
against bacterial translocation in the gut.67 By lowering the T 
cell levels in the blood and preventing a proper immune response 
upon infection, there is an increased likelihood of future sus-
ceptibility to infections. A clinical trial in Brazil analyzing the 
immune stimulatory abilities of a mixture of Bifidobacterium 
bifidum and Streptococcus thermophilus found that CD4+ T cell 
counts could be increased from a mean of 580 cells mm-3 in the 
control group to 673 cells mm-3 in the probiotic group.37 This 
study in HIV infected children age 2–12 years, demonstrated an 
organizations, insurance companies, cattle trade, schools, hospi-
tals and large employers also help. Product development should 
not only focus on dairy, but also consider traditional fermenta-
tion of home grown foods,52 as well as dried preparations.
In the study being proposed here, the probiotic would be 
provided in the form of a sachet which can be added to the 
meals participants regularly consume. Sachets are already used 
in some resource disadvantaged countries and products such 
as micronutrient-rich Moringa are used widely by HIV/AIDS 
patients to fortify their diet. The possibility of adding a probi-
otic strain(s) to an existing sachet should be explored. Several 
European probiotic producers have offered to provide their 
strains free-of-charge in sachet form, for the envisaged study, 
but long term implications will need to be considered. If such 
companies could also assist with transferring the sachet pro-
duction capabilities to a local site near where the trial is being 
performed, this would encourage long term sustainability if the 
product is effective. Using a sachet avoids complications of ask-
ing participants to consume a food product which they may not 
like. However, a probiotic yogurt or other nutrient rich food 
could also supply nutrients such as vitamin A, zinc and gluta-
mine which have been shown to improve gut conditions.53-55 In 
addition, administering probiotics early allows for intervention 
when the child is most sensitive to the environment and is grow-
ing both cognitively and physically.56,57 The rationale for use of 
a placebo powder without the probiotic, in addition to blinding 
and assessing efficacy is that this follows standard care of chil-
dren in these impoverished communities; that is, they do not 
receive interventional therapy.
Participants would be divided into control or experimental 
groups randomly; neither the participant nor investigators would 
know the designation of the participant, to avoid bias. The study 
proposed herein would involve a longitudinal follow-up of chil-
dren for up to two years minimum, in order to note any long term 
differences such as height and weight gain in addition to changes 
in frequency/intensity of diarrheal episodes and effects on the 
gut microbiota. It also allows for determination of improvements 
in quality of life. Recruitment would commence in children at 
age six months and after baseline data was collected, the probi-
otic intervention would begin at month seven and continue until 
the children are 12–18 months of age.56,58 The children would 
be followed until age 2, with measurements taken monthly. It 
is accepted that the microbiota of a breast-fed child differs from 
formula fed children.56 As breast feeding correlates with fewer 
episodes of diarrhea, when breast feeding ceases around 7 months 
of age, the provision of a probiotic supplement at this time point 
could help protect the weaning child at a critical time of growth.
While the focus is on reducing diarrhea, simply counting this 
as the only outcome marker would limit the power and impact of 
the study. For example, improving the quality of life of patients, 
reducing mortality, reducing stunting, improving weight gain, 
showing a long term impact on cognitive function, and improv-
ing the overall effect on the public health burden are all integral 
to success. Public health workers need to be aware of the benefit 
of probiotics and this is where improvement in education could 
be crucial.
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unsuitable for viral replication. Loss of Th17 cells and reduction 
of precursor CD161 CD4 cells, which may limit Th17 recon-
stitution in untreated HIV infection has now been shown to be 
associated with a gradual decline in T-regs, increased immune 
activation and disease progression.72 There has been some con-
nection between probiotics and increased T-reg cell activity,73 but 
not yet related to HIV. By including T-reg cell functional data 
in the proposed study, the plasma viral levels would be measured 
to determine if changes in cell responses correlate with lowering 
viral load.
The gut microbiota will also be analyzed using stool samples 
collected from study participants both in control and experi-
mental groups, as for the diarrhea study above. Analysis will 
be done using a high throughput sequencing platform such as 
Illumina which has been used to sequence the vaginal micro-
biota down to species level.63 The use of Illumina or a similar 
high throughput system is attractive, as DNA samples can be 
isolated on site but when stored properly at -80 degrees Celsius 
or on liquid nitrogen, they can last for years. This allows the 
investigators to return to their own institutions and have the data 
analyzed if such sequencing facilities are not present on site. In 
addition, with the advancement of the technology, the prices for 
sequencing are becoming very economical. This makes it fea-
sible to perform sequencing of large sample sizes and improve 
statistical power. Particular interest will be placed in how species 
abundance changes over the course of infection and if probiotic 
use has an effect on these, inflammation, diarrhea, weight/body 
mass index BMI and energy.74 The ability of probiotics to modify 
weight and energy is of interest, as the primary goal of such a 
study is to improve quality of life. The Medical Outcomes Study 
HIV Health Survey (MOS-HIV) is a very widely used quality 
of life measure. It includes 35 items that address the domains 
of: role function, pain, physical functioning, cognitive function-
ing, overall health perception, mental health and vitality.75 The 
weighted sub-scores in these domains are then combined to pro-
duce two summary scores measuring physical health and mental 
health. By using such a scoring system, it is possible to determine 
quality of life and notice differences in experimental vs. control 
group.
Important Additional Issues
Clinical designs such as those proposed allow opportunities to 
test probiotic effects. This is required in order to justify setting 
up a community kitchen with the goal of providing probiotic 
benefits daily for members of the community. But, the long term 
establishment of an operation requires acknowledging feasibil-
ity issues and how the project will be managed embracing local 
people and their customs. In approaching the proposed stud-
ies, careful consideration must also be given to strain selection. 
Unfortunately this decision must be based upon limited under-
standing of how probiotics might work in people challenged 
with malnutrition and infection. Still, strains can be selected 
with respect to safety, some in vitro documentation that supports 
the proposed mechanisms of action, and their ability to produce 
a food with satisfactory taste and texture for the users. These 
immune stimulatory effect induced by probiotics. When given in 
conjunction with antiretroviral drugs, probiotic supplementation 
improved CD4+ T cell counts and reduced viral load, delaying 
clinical onset of AIDS.
The proper functioning of a child’s immune system to com-
bat infections relies on their nutritional status. Nutrients regulate 
the priming of immune responses postnatal through effects on 
signal transduction pathways and immune cell development.68 
Differences have been found in the ability of neonates to respond 
to pathogens depending on their nutritional status and intake 
of micronutrients including vitamins A and E, calcium, iron 
and zinc.39 A probiotic supplement delivered in a medium, such 
as yogurt, which can be enriched with micronutrients would 
provide additional fortification to the child’s immune system. 
Probiotics delivered to children at a young age can fortify the gut 
microbiota. This is especially important for children not being 
breast-fed by HIV-infected mothers due to the potential of HIV 
transmission via human milk.69 One study has shown that the 
number of lactic acid bacteria present in the intestinal tract of 
children infected with HIV is far less than in healthy children, 
with Lactobacillus plantarum and Bifidobacterium spp not found 
in the infected children.70 This implies that replenishment of 
these species might provide benefits.
A study design similar to the successful Brazilian study cited 
earlier37 would verify whether nutrition supplemented with pro-
biotics can improve the quality of life of HIV-infected children. 
Enrolment would consist of children aged 2–10 with CD4+ T 
cell counts between 200–500 cells/μL, without co-infection 
and receiving highly active anti-retroviral treatment (HAART). 
Note, this will need to be assessed and controlled as treatment 
regimens vary by country and patient profile. Targeting children 
allows for signs of early intervention to be noticed, such as reduc-
tion of diarrhea and secondary infections caused from a weak-
ened immune state. Participants would be randomized into two 
groups; with the control group receiving unsupplemented yogurt 
and the experimental group receiving yogurt with probiotic 
supplementation. In this instance, no prebiotics would be added. 
Baseline measurements would be taken daily for one month to 
determine fluctuation in T cell levels and estimates of viral load. 
Testing would then commence with the groups receiving pro-
biotic supplemented yogurt or unsupplemented yogurt daily for 
two months. Measurements would ideally be taken every day (or 
twice weekly depending upon compliance and practicality) once 
treatment began. Following the two month intervention period, 
treatment with probiotic yogurt and daily measurements would 
stop but, participants would be followed and have measure-
ments taken weekly for the next year, to determine longitudinal 
changes.
Counts of CD4+ T cells and T-regulatory (T-reg) cells (includ-
ing Th17 cells) would be examined to aid in determination of 
immune stimulatory effects of the intervention. As this was used 
in the Brazilian study,37 comparisons can be made with the new 
findings. In HIV-resistant woman there are higher amounts of 
T-reg cells compared to non-resistant woman.71 T-reg cells are 
believed to suppress CD4+ and CD8+ T cell activation. By sup-
pressing activity and transcription, virus infected cells become 
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owners to allow access to the organisms for what amounts to 
humanitarian studies. These partnerships would constitute win-
win scenarios in which industries controlling the strains would 
have their interests understood and protected in the study, while 
allowing researchers access to the organisms. More importantly, 
with the studies’ success, measures could be put in place to allow 
long term use of the strains in these settings. One option would 
be to allow not-for-profit strain usage, such as granting the local 
community the ability to set up community kitchens,48 and leav-
ing the option with the intellectual property holder to use their 
strain in the future in these countries if they decide to set up 
commercial ventures. Freedom to publish results must also be 
considered in these partnership negotiations.
In terms of the strain(s) itself, the basis for selection is far from 
easy. In both diarrhea treatment and use for improving gut health 
in HIV subjects, a case could be made for a strain that increases 
epithelial barrier function and upregulates antimicrobial immu-
nity,33,34 as tested in vitro. The in vitro ability to adhere to epithe-
lial cells or mucus, or to inhibit pathogen growth may or may not 
be essential. Probiotic strains can confer beneficial properties as 
planktonic cells, and they can adhere by a range of specific and 
non-specific mechanisms that may not be assessed in the assays 
commonly used. Also, a large range of microbial pathogens can 
cause diarrhea, so it can be difficult to prove a correlation between 
pathogen growth inhibition in vitro and in vivo outcome. The 
exception to the latter point is Lactobacillus salivarius UCC118 
which in animal studies has been shown to have a bacteriocin 
essential for preventing infection by Listeria monocytogenes.78 Cell 
line studies could also be used to identify strains that inhibit viral 
invasion and replication.79,80 The concept of using a multi-strain 
product is worthy of consideration, but requires not only mecha-
nistic justification (one strain that upregulates barrier function 
and another that stimulates innate immunity), but also step-wise 
evidence that the addition of strains improves the effectiveness of 
a single-strain product.
(3) Setting up a long lasting operation. The freedom-to-
operate issue is critical to resolve because in order to improve 
the lives of those living in the developing world, any positive 
findings related to probiotic studies need to translate into long 
term benefits for the communities in which the studies were 
performed. Questions must be asked before the study begins, 
such as what will be the best way to deliver the probiotic, (i.e., 
a sachet, a yogurt or in milk?). What financial considerations 
must be resolved to allow some future control by the local com-
munity over the strains, supplies, safety, quality assurance, fixed 
costs and maintenance of a viable production set-up. In Mwanza 
Tanzania, a community kitchen is operated by the local Kivulini 
woman’s group with support from the National Institute for 
Medical Research, and other partners along with The University 
of Western Ontario.48 This kitchen produces a probiotic yogurt 
which is given to all-comers, including people infected with HIV. 
Mimicking such a set up and adapting it to different locations 
would allow for an initial set-up which can be modified to suit 
the cultural and specific needs of the population. Members of 
these communities are impoverished and cannot afford to pay 
high prices for probiotic products. Thus, funds must be secured 
selection criteria are crucial, along with careful identification of 
subjects more likely to response.46
Another issue comes from understanding how clinical trials 
are performed in resource limited settings. Factors to consider 
include cultural, political, language and ethical factors in recruit-
ment of subjects.76,77 Establishment of studies may require special 
partnerships either with government support or local research 
institutions in order to succeed. Local researchers and commu-
nity leaders are critical to the development, conduct and sus-
tainability of implementation of ethical and relevant outcomes. 
Three particularly important issues must be considered.
(1) Funding. Currently clinical trials related to probiotics are 
not receiving the attention of many governments and funding 
agencies. Despite best efforts of dedicated and respected scientists 
and data proving a positive effect of probiotics against diarrhea, 
HIV and other infections, the generalized misinformation on 
probiotic use and effects has posed a challenge to secure funding 
of these important clinical trials. In order to counter this, prog-
ress must be made on understanding how probiotics work. Focus 
should also be put on understanding how the strains of inter-
est grow, their metabolic pathways, and how they react in vitro 
with other strains. While these are important considerations, the 
complexity of the probiotic field suggests that clinical trials con-
ducted in collaboration with evaluating mechanisms of probiotic 
response may be the most efficient means of developing the basic 
science and clinical applications of the field. Sequencing of the 
genome of the strain(s) to be used can provide valuable data and 
permit a transcriptomic study to assess which genes might be 
upregulated in vivo. Such studies are expensive and not yet part 
of trials in developed countries, so it is unrealistic in the settings 
discussed above. Nevertheless, they remain a worthy goal.
Awareness of the scientific (and non-scientific) community, 
including grant review panel members, needs to be raised so there 
is an understanding of the importance and beneficial impact pro-
biotic use can have on health and quality of life. Product safety 
must always be an issue, even though past studies have shown 
minimal risk of probiotic yogurts. For locally-produced trial 
material, safety standards must be established and products mon-
itored regularly and thoroughly, in particular microbial culturing 
should be performed to rule out contamination by pathogens. 
Storage of products at point-of-distribution to point-of-ingestion 
also requires safety monitoring for tampering. In addition, the 
safety of study subjects must be considered, either for them trav-
eling to and from the study site, or for issues related to their par-
ticipation, such as being ostracized in their community.
(2) Selection of and access to strains. Currently the majority 
of strains are owned by for-profit companies such as Chr Hansen, 
Danisco, Lallemand, Danone, General Mills, Nestle and others. 
These companies have the right to control who has access to the 
strains and what studies can be performed with them or their 
by-products. Advancement of scientific knowledge gained from 
projects aimed at improving the lives of millions of people living 
in countries where such strains and products are not available 
would ultimately benefit business partners. While ownership and 
proper management of such strains are important in terms of 
business ventures, partnerships need to be established with strain 
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scenario also relies upon the goodwill of the strain owner to 
provide stock cultures. Ideally, if dried powdered strains in pre-
set vials could be provided, it would allow for easy preparation 
of the end-product.
A road map for the design of clinical studies which attempts 
to summarize key steps and outcomes is presented in Figure 1.
Recommendations
In conclusion, it was felt four key points must be addressed in 
order to improve probiotic clinical trials in resource disadvan-
taged settings.
(1) Identify the right population. Researchers must under-
stand the population, not only its health challenges, but just as 
important its cultural, social, demographic and ethical nuances. 
For example, factors such as the daily diet, whether children are 
being breast-fed, whether the same child receives the study prod-
uct each day, whether health records for the subjects are reliable, 
and what factors ensure compliance are much greater challenges 
initially from developed countries, and used to supplement local 
in-kind support, while conjointly lobbying for local funds (such 
as through the Tanzanian Commission for AIDS, TACAIDS) 
which for example could pay for HIV/AIDS patients to receive 
the yogurt for free.
Maintaining product quality is crucial when setting up such 
an operation. Ensuring reproducibility of the product, inclu-
sion of the probiotic in all batches, and having the ability to 
problem solve (such as if taste and texture change) cannot be 
understated. Contamination needs to be avoided at every level 
of production and distribution, or quality will not be retained 
and possible adverse health effects may occur. Stocks of strains 
could be pre-made, kept frozen at a nearby institute or hos-
pital, then prepared and delivered to the kitchen as needed. 
However, this requires buy-in from the institute/hospital site. 
Alternatively, stocks could be kept at the kitchen and prepared 
as needed, in which case personnel training, access to equip-
ment including freezers, refrigerators and incubators is needed 
and external, independent monitoring arranged. The latter 
Figure 1. Road map for the design of the clinical study.
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function. Determining whether the subject has diarrhea lasting 
7 days or longer (“prolonged diarrhea”) may provide a helpful, 
simple marker of the impact of the treatment on overall diarrhea 
burden and growth shortfalls. Metabolic by-products recoverable 
from feces might also provide markers of the host’s response to 
the intervention,82 although these tests are expensive, only per-
formed at a few sites and not available in resource disadvantaged 
countries. It is known that lactobacilli, bifidobacteria and prebi-
otics can alter the metabolic print-out,83 so if a preferred readout 
associated with health could be identified, the administration of 
different candidate probiotics or prebiotics could be assessed in 
one or two volunteers, to see if they achieve resolution of diarrhea 
and restoration of health based upon the metabolome.
(4) Partnerships with industry, communities and govern-
ment. Partnerships are vital for successful implementation of 
clinical studies in resource-poor communities. These must 
include local community leaders to engage subjects and help sub-
jects understand the ethical, practical and compliance issues of 
the study and to educate the community about expectations. An 
ideal team may consist of government officials who can provide 
access to funds and oversee health and security issues; scientists 
and clinicians who can promote the study amongst the popula-
tion, help recruit patients and coordinate sample collection and 
analysis; local business people such as farmers to provide milk 
in a reliable and consistent manner; donors to provide payments 
for subject travel; and people to distribute the product. Cultural 
or religious leaders may also be required to ensure the project is 
aligned with community values.
Conclusion
A lack of information and clinical trial data have made it dif-
ficult to secure funding for these studies, to date. Public aware-
ness of the scientific (and non-scientific) community needs to 
be raised so there is an understanding of the importance and 
beneficial impact probiotic use can have on public health and 
quality of life in the developing world. We would like to con-
clude with an invitation to industry, government and scientific 
institutions to join us and participate in these efforts to alleviate 
disease and improve the quality of life of those in need.
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in many instances in the developing world where education lev-
els are often very low. Baseline assessment of the microbiota will 
be important to understand whether or not subjects respond in 
the same manner to probiotic treatment as a North American 
or European citizen who had been shown to respond to similar 
treatment. Knowing how to maintain compliance if the study 
subjects (say children) may be left alone for many hours of the 
day is crucial. This may require working with a local clinic or 
community facility where children can come to receive treatment 
daily. It may also require recruiting an initial large sample size 
if a large percentage may be expected to drop out or be non-
compliant. The disease of interest must also be validated in all 
participants. Control subjects must be equally prone to have the 
disease so that comparisons can be made on the extent of the 
effect for probiotic treatment.
(2) Selecting study strains. With the emphasis being on treat-
ing diarrhea and improving health/gut function and quality of 
life of those suffering from HIV, the selection of strains with an 
immunomodulatory function and an ability to improve gut bar-
rier function need to be considered. Combination strains must be 
shown to complement each others’ activity and survive to appro-
priate levels in the yogurt that is the delivery vehicle. In vitro 
tests may be helpful, if not already performed on the strains, but 
translating the results to the clinical setting must occur with cau-
tion. Decisions must be made about whether to recover the strain 
from the stool or how best to establish if the strain is functioning 
in some or all subjects. Such research questions will require a 
separate budget. Advancements in basic knowledge attained from 
the trials will benefit others in the future.
(3) Identifying biomarkers. How do we measure the effect we 
are looking for in an individual subject? For analyzing diarrhea 
would one only look at reduction of episodes as an effect of pro-
biotic activity? Identification of biomarkers is crucial in order to 
track clinical outcomes. A biomarker is a characteristic that can 
be objectively measured and evaluated as an indicator of normal 
and disease processes or pharmacological response.81 A condition 
such as diarrhea has been shown to affect the body in many ways 
including being detrimental to growth, adversely impacting long 
term cognitive function, gut health and levels of energy. The abil-
ity to measure, particularly long term, biomarkers of relevance to 
the test community is critical. Quality of life factors in develop-
ing countries are not ‘biomarkers’ per se, nor necessarily the same 
as in developed countries. But, the ability to have enough energy 
to work each day may certainly be as important as T-reg cell sta-
tus or LPS levels in the blood indicating improved gut barrier 
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